Shares in Ocular Therapeutix (NSDQ:OCUL) rose this morning after the company beat expectations on Wall Street with its fourth quarter earnings, but missed analysts’ sales estimates.
The company is facing a slew of class action suits from investors, as well as a probe by the Securities and Exchange Commission regarding its post-surgical pain relief implant, Dextenza.
Get the full story at our sister site, Drug Delivery Business News.
The post Facing legal woes and SEC probe, Ocular Therapeutix posts mixed Q4 appeared first on MassDevice.